|
gptkbp:instanceOf
|
vaccine
|
|
gptkbp:administeredBy
|
birth
6-18 months
1-2 months
|
|
gptkbp:approvedBy
|
gptkb:World_Health_Organization
gptkb:U.S._Food_and_Drug_Administration
1981
|
|
gptkbp:boosterRecommended
|
no (for most people)
|
|
gptkbp:brand
|
gptkb:Recombivax_HB
gptkb:Engerix-B
gptkb:Heplisav-B
gptkb:Twinrix
|
|
gptkbp:broadcastOn
|
3 doses
|
|
gptkbp:category
|
public health
immunization
infectious disease prevention
|
|
gptkbp:combines
|
gptkb:Hepatitis_A_vaccine
|
|
gptkbp:contains
|
hepatitis B surface antigen
|
|
gptkbp:contraindication
|
severe allergic reaction to previous dose
|
|
gptkbp:developedBy
|
gptkb:Maurice_Hilleman
|
|
gptkbp:durationOfImmunity
|
at least 20 years
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Hepatitis B Vaccine
|
|
gptkbp:includedIn
|
gptkb:WHO_Essential_Medicines_List
|
|
gptkbp:indication
|
adults
infants
healthcare workers
people at risk of hepatitis B infection
|
|
gptkbp:marketedAs
|
gptkb:Sanofi_Pasteur
gptkb:Merck_&_Co.
gptkb:Dynavax_Technologies
GlaxoSmithKline
|
|
gptkbp:pregnancyCategory
|
safe
|
|
gptkbp:prevention
|
gptkb:Hepatitis_B
|
|
gptkbp:routeOfAdministration
|
intramuscular injection
|
|
gptkbp:sideEffect
|
fever
fatigue
soreness at injection site
|
|
gptkbp:storage
|
2-8°C
|
|
gptkbp:type
|
recombinant vaccine
subunit vaccine
|
|
gptkbp:WHOATCCode
|
gptkb:J07BC01
|
|
gptkbp:bfsParent
|
gptkb:Immunization_Clinic
|
|
gptkbp:bfsLayer
|
5
|